%20INC./other/GINWA_ENTERPRISE_GROUP_INC.-logo.png)
GINWA ENTERPRISE (GROUP) INC. — Investor Relations & Filings
Ginwa Enterprise (Group) Inc. operates as a diversified conglomerate focused on the research, development, manufacturing, and distribution of medical products. The company's portfolio includes traditional Chinese medicines, chemical drugs, and biological preparations targeting therapeutic areas such as cardiovascular health, anti-infectives, and digestive disorders. In addition to its medical operations, the group is involved in high-tech development, real estate, and strategic investment activities. The organization prioritizes technological innovation and adheres to rigorous quality control standards across its production facilities. It serves a broad market base, focusing on the modernization of traditional medicinal practices and the integration of advanced biotechnology into its product offerings.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 关于延期回复上海证券交易所对公司2019年年度报告信息披露监管问询函的公告 | 2020-05-21 | Chinese | |
| 关于收到上海证券交易所对公司2019年年度报告的信息披露监管问询函的公告 | 2020-05-14 | Chinese | |
| 关于公司持股5%以上的股东股权转让的提示性公告 | 2020-05-13 | Chinese | |
| 收到上海证券交易所关于公司2019年年报有关非经营性资金占用事项的监管工作函的公告 | 2020-05-05 | Chinese | |
| 独立董事对非标准审计意见涉及事项的独立意见 | 2020-04-29 | Chinese | |
| 董事会关于非标准财务审计意见内控审计意见涉及事项的专项说明 | 2020-04-29 | Chinese |
Browse filings by year
26 years- 2026 57 filings
- 2025 109 filings
- 2024 101 filings
- 2023 125 filings
- 2022 133 filings
- 2021 103 filings
- 2020 144 filings
- 2019 67 filings
- 2018 80 filings
- 2017 105 filings
- 2016 103 filings
- 2015 54 filings
- 2014 47 filings
- 2013 28 filings
- 2012 35 filings
- 2011 44 filings
- 2010 30 filings
- 2009 42 filings
- 2008 62 filings
- 2007 75 filings
- 2006 62 filings
- 2005 37 filings
- 2004 21 filings
- 2003 16 filings
- 2002 29 filings
- 2001 6 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2020
15 filings
| |||||
| 40275475 | 关于延期回复上海证券交易所对公司2019年年度报告信息披露监管问询函的公告 | 2020-05-21 | Chinese | ||
| 40275471 | 关于收到上海证券交易所对公司2019年年度报告的信息披露监管问询函的公告 | 2020-05-14 | Chinese | ||
| 40275464 | 关于公司持股5%以上的股东股权转让的提示性公告 | 2020-05-13 | Chinese | ||
| 40275452 | 收到上海证券交易所关于公司2019年年报有关非经营性资金占用事项的监管工作函的公告 | 2020-05-05 | Chinese | ||
| 40275442 | 独立董事对非标准审计意见涉及事项的独立意见 | 2020-04-29 | Chinese | ||
| 40275434 | 董事会关于非标准财务审计意见内控审计意见涉及事项的专项说明 | 2020-04-29 | Chinese | ||
| 40275425 | 独立董事2019年度述职报告 | 2020-04-29 | Chinese | ||
| 40275415 | 2020年第一季度报告正文 | 2020-04-29 | Chinese | ||
| 40275405 | 国金证券关于金花企业(集团)股份有限公司非公开发行保荐工作总结报告 | 2020-04-29 | Chinese | ||
| 40275392 | 国金证券关于金花企业(集团)股份有限公司2019年度持续督导报告书 | 2020-04-29 | Chinese | ||
| 40275385 | 关于使用暂时闲置资金购买理财产品的公告 | 2020-04-29 | Chinese | ||
| 40275375 | 第八届监事会第十六次会议决议公告 | 2020-04-29 | Chinese | ||
| 40275366 | 2020年度投资者关系管理计划 | 2020-04-29 | Chinese | ||
| 40275357 | 国金证券关于金花企业(集团)股份有限公司2019年度募集资金存放及使用情况的专项核查报告 | 2020-04-29 | Chinese | ||
| 40275350 | 监事会关于董事会关于非标准审计意见涉及事项的专项说明 | 2020-04-29 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
GINWA ENTERPRISE (GROUP) INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56468/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56468 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56468 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56468 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56468}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for GINWA ENTERPRISE (GROUP) INC. (id: 56468)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.